Description

Medical imaging such as CT, MRI and PET scans can be used to make a diagnosis or prognosis, select therapy, monitor responses to therapy and yield pharmacokinetic information about drugs. EORTC’s Imaging research aims to establish and maintain the scientific and clinical value of advanced imaging. We develop specific analytical, review and quality control procedures in the context of EORTC clinical trials.

Related Projects

  • IMI QuIC-ConCePT – Quantitative Imaging in Cancer: Connecting Cellular Processes with Therapy. The EORTC is coordinating the project. QuIC-ConCePT aims to provide drug developers with imaging biomarkers that can show earlier and more accurately how patients’ tumors respond to drugs in cancer clinical trials. Imaging biomarkers are being tested within series of clinical validation studies including the trial EORTC-1217-IG-LCG “Evaluation of 3′-deoxy-3′-[18F]fluorothymidine -PET and diffusion weighted imaging -MRI in patients with early stage non-small cell lung cancer treated with a platinum-based doublet as preoperative chemotherapy” and Trial EORTC-1423-IG-GITCG “Evaluation of diffusion weighted imaging -MRI in patients with resectable liver metastases from colorectal cancer treated with fluoropyrimidine-based chemotherapy as preoperative treatment”.
  • IMI2 Tristan – Imaging Biomarkers for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment. The EORTC is coordinating the project.  The 5-year project will focus on validation of translational imaging methods as potential imaging biomarkers for  the assessment of liver toxicity, lung toxicity and the bio-distribution of biologics. (No website available yet)
  • EORTC RP 1106: A three-step study on the feasibility and prognostic value of rCBV in patients with GBM.
    (project leader: M. Smits) Three steps project:

    • Technical evaluation of acquisition a standardized protocol, centralized data storage, quality assurance.
    • Compare quantification to select and test post-processing tools, to standardize methodology for rCBV measurements and to assess inter- and intra- reader variability.
    • Prognostic value of rCBV to predict patient outcome.
      A publication on repeatability and reproducibility of relative cerebral blood volume measurement in recurrent glioma will be submitted soon.
  • EORTC RP 1547 (PICRIB): Platform for imaging in clinical research in Brussels
    (project leader: J. Vandemeulebroucke)
    PICRIB is a clinical imaging platform that will enable the interoperability of the Brussels university hospitals and facilitate the patient mobility. EORTC is the WP7 lead, and provides guidance regarding standards applicable for imaging used in clinical trial e.g. images acquisition and interpretation, inter-institution quality assurance/ quality control.

Research Group

Group documents
  • Chair

    Yan Liu

    EORTC Headquarters

    Brussels, Belgium

  • Secretary

    Laure Fournier

    Hôpital Européen Georges Pompidou

    Paris, France

  • Treasurer

    Christophe Deroose

    U.Z. Leuven

    Leuven, Belgium

Additional People

  • L. Bidaut - Lincoln, GB

    Chair of Radiomics subcommittee

    University of Lincoln

  • C. Caramella - Villejuif, FR

    Chair of Immuno-Imaging subcommittee

    Gustave Roussy

  • N. deSouza - Sutton, GB

    Chair of Bone- and Oligomets subcommittee

    Royal Marsden Hospital Sutton